| Name | Title | Contact Details |
|---|
Unison Risk Advisors is one of the top privately-held insurance brokerages in the nation. Through its regional operating companies, Unison Risk Advisors provides risk management services, commercial property and casualty insurance, employee benefits and health insurance, personal and life insurance, and retirement plan services to corporate and individual clients in a diverse set of industries. Unison Risk Advisors is committed to an independent brokerage service model guided by the belief that clients are best served by professionally managed and well-resourced firms that can act independently upon the best interests of the client.
9to5 Seating is a vertically-integrated, privately owned company, founded in 1986, which specializes in the design and production of ergonomic office seating to accommodate the rigorous demands of todays office environments. 9to5 Seating presents an extensive collection of executive, task, guest, conference, stool and lounge seating. Customization is an everyday demand that 9to5 Seating welcomes; seats, controls, arms, chair adjustments, finishes, and upholstery options are plentiful. 9to5 Seating combines its state-of-the-art, in-house manufacturing systems with a commitment to continuous improvements in all phases of the operation. With over 500,000 sq. ft. of manufacturing resources, we are confidently empowered to deliver products offered at unparalleled pricing, with quality built into every phase of manufacturing. Our dedication to becoming the leader in office furniture requires that we go beyond customer expectations. We strive to provide quality products, plethora of upholstery options, express shipping superior customer service and the best warranty as possible.
BHS Corrugated – leading provider of solutions for the corrugated industry BHS Corrugated is the leading provider of solutions for the corrugated industry with 3,000 employees at headquarters in Weiherhammer, Germany as well as in more than 20 countries. As Lifecycle Partner, BHS Corrugated is consistently strong across the entire product and service range: from development and production, to installation and maintenance, to a variety of innovative Lifecycle Service solutions in the areas of corrugating rolls, individual machines, complete corrugators, industry 4.0, logistics and soon to come digital print in- and outside the corrugator. Significant aspects of digitalization, primarily regarding the optimization of process parameters and increasing degrees of automation and production efficiency, have been central issues of BHS Corrugated for many years. To meet the requirements of its customers as precisely as possible and to be always state-of-the-art, BHS Corrugated reinvests close to 5 percent of its turnover in research and development. In addition to its core business, BHS Corrugated supports different social projects, for example the familys own foundation "Angels for Children" or the "Lars und Christian Engel Stiftung (LUCE Trust)", which supports technological and economic development in the region. Contact: BHS Corrugated Maschinen- und Anlagenbau GmbH Paul-Engel-Str. 1 92729 Weiherhammer info@bhs-world.com Tel. +49 9605 919 0 bhs-world.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.